ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 454

Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study

Jordan Van Dyk1, Bryan Heard 1 and Cheryl Barnabe 1, 1University of Calgary, Calgary, AB, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: prognostic factors and biomarkers, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Determining the prognosis of rheumatoid arthritis (RA) could guide more precise treatment selection, optimizing outcomes while minimizing unnecessary therapeutic exposures. It is important that potential biomarkers have widespread availability and provide meaningful input in clinical decision making. While CRP and ESR have been shown to be moderately associated with disease activity and severity, there continues to be uncertainty regarding the utility of these as they may be elevated in other conditions, or be normal even during severe clinical inflammation. While RF and anti-CCP positivity are considered to be associated with more treatment refractory RA, those who are autoantibody negative may experience a negative disease trajectory as well due to lack of recognition of disease and introduced delays in treatment initiation. Our objective was to employ principal component analysis to investigate if biomarkers could determine sub-groups of disease severity.

Methods: RA patients were recruited from a single centre to a cross sectional study initiated to investigate influences on disease trajectory (n=145). ESR, CRP, RF, and anti-CCP collected at enrolment to the study were used in the principle component analysis (PCA) to create 2 components, which were subsequently used in k-means clustering (K=3) to demarcate the patient groups. Function (Health Assessment Questionnaire), Physician Global Assessments (MD Global), and Patient Global Assessments (Pt Global) were divided into 3 tertiles of disease activity (mild, moderate, and severe) and used as metrics of disease severity to describe the patient groups identified by PCA and K-means.

Results: Based on correlation analysis, ESR and CRP had a moderate positive relationship with each other (r=0.67), but no correlation with HAQ, Pt Global, or MD Global. Furthermore, there was no relationship between individual serological markers and disease activity as reported by HAQ, Pt Global, or MD Global (r< 0.25 for all). PCA revealed the presence of three visual groupings of data points (PC1, PC2 and PC3), that were then confirmed with K-means clustering (Figure 1). ESR and CRP weighed most heavily in PC1, while PC2 was predominantly influenced by anti-CCP and RF. Disease severity assessments illustrate that PC3 had a higher percentage of severe disease and PC2 showed a higher percentage of mild disease (Figure 2).

Conclusion: Sub-populations with unique serological biomarker combinations that predict disease severity are identifiable. The sub-group that was not influenced as strongly by serology was the group identified to have the largest proportion of patients with mild disease. Furthermore, the group with the highest proportion of patients with severe disease was most heavily influenced by ESR and CRP, and the group with the next highest percentage of severe disease was influenced predominantly by anti-CCP and RF. This suggests 2 unique populations with higher serological values and various weighted combinations of ESR and CRP, or anti-CCP and RF, seem to display RA with a more severe phenotype. Further studies will need to be undertaken to identify factors that make these RA groups unique.


Disclosure: J. Van Dyk, None; B. Heard, None; C. Barnabe, None.

To cite this abstract in AMA style:

Van Dyk J, Heard B, Barnabe C. Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/principal-component-analysis-identifies-unique-sub-populations-in-rheumatoid-arthritis-using-a-combination-of-serological-biomarkers-a-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/principal-component-analysis-identifies-unique-sub-populations-in-rheumatoid-arthritis-using-a-combination-of-serological-biomarkers-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology